Relationship between anti-apoptotic proteins survivin and Bcl-2, and response to treatment in patients undergoing post-operative RT for laryngeal cancer: A pilot study

Journal of Oral Pathology and Medicine

Volumn 42, Issue 4, 2013, Pages 339-344

  Marioni, Gino ^a   Staffieri, Alberto ^a   Lionello, Marco ^a   Tealdo, Giulia ^a   Staffieri, Claudia ^a   Giacomelli, Luciano ^a   Friso, Maria Luisa ^b   Stramare, Roberto ^a   Ottaviano, Giancarlo ^a   Blandamura, Stella ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Bcl 2; Laryngeal carcinoma; Post operative radiotherapy; Prognosis; Survivin

Indexed keywords

PROTEIN BCL 2; SURVIVIN;

ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CORRELATIONAL STUDY; CYTOPLASM; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; MALE; PILOT STUDY; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; TREATMENT RESPONSE;

AREA UNDER CURVE; CARCINOMA, SQUAMOUS CELL; CELL NUCLEUS; CYTOPLASM; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LARYNGEAL NEOPLASMS; LYMPHATIC METASTASIS; MALE; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PILOT PROJECTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; ROC CURVE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84875806541     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/jop.12020     Document Type: Article

References (23)

1. Marioni G, Marchese-Ragona R, Cartei G, Marchese F, Staffieri A. Current opinion in diagnosis and treatment of laryngeal carcinoma. Cancer Treat Rev 2006; 32: 504-15.
2. Strojan P, Ferlito A, Langendijk JA, Silver CE. Indications for radiotherapy after neck dissection. Head Neck 2012; 34: 113-9.
3. Marioni G, D'Alessandro E, Bertolin A, Staffieri A. Survivin multifaceted activity in head and neck carcinoma. Current evidence and future therapeutic challenges. Acta Otolaryngol (Stockh) 2010; 130: 4-9.
4. Church DN, Talbot DC. Survivin in solid tumors: rationale for development of inhibitors. Curr Oncol Rep 2012; 14: 120-8.
5. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003; 22: 8581-9.
6. Azmi AS, Wang Z, Philip PA, Mohammad RM, Sarkar FH. Emerging Bcl-2 inhibitors for the treatment of cancer. Expert Opin Emerg Drugs 2011; 16: 59-70.
7. Straten P, Andersen MH. The anti-apoptotic members of the Bcl-2 family are attractive tumor-associated antigens. Oncotarget 2010; 1: 239-45.
8. Kelly PN, Strasser A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ 2011; 18: 1414-24.
9. Sobin LH, Gospodarowicz MK, Wittekind C, eds. TNM classification of malignant tumors, 7th edn. Oxford: Wiley-Blackwell, 2009.
10. Marioni G, Agostini M, Bedin C, et al. Survivin and laryngeal carcinoma prognosis: nuclear localization and expression of splice variants. Histopathology 2012; 61: 247-56.
11. Samm N, Werner K, Rückert F, Detlev Saeger H, Grützmann R, Pilarsky C. The role of apoptosis in the pathology of pancreatic cancer. Cancers 2011; 3: 1-16.
12. Fulda S. Inhibitor of apoptosis (IAP) proteins as therapeutic targets for radiosensitization of human cancers. Cancer Treatment Rev, 2012; 38: 760-6.
13. Lera J, Lara PC, Perez S, Cabrera JL, Santana C. Tumor proliferation, p53 expression, and apoptosis in laryngeal carcinoma: relation to the results of radiotherapy. Cancer 1998; 83: 2493-501.
14. Jiang H, Yang BB. p53, epidermal growth factor receptor and proliferating cell nuclear antigen in laryngeal squamous cell carcinoma are not predictive markers for the effect of adjuvant radiotherapy. Acta Otolaryngol (Stockh) 2009; 129: 101-7.
15. Marioni G, Blandamura S, Loreggian L, et al. Laryngeal carcinoma prognosis after postoperative radiotherapy correlates with CD105 expression, but not with angiogenin or EGFR expression. Eur Arch Otorhinolaryngol 2011; 268: 1779-87.
16. Lionello M, Blandamura S, Loreggian L, et al. High mTOR expression is associated with a worse oncological outcome in laryngeal carcinoma treated with postoperative radiotherapy: a pilot study. J Oral Pathol Med 2012; 41: 136-40.
17. Dong Y, Sui L, Watanabe Y, Sugimoto K, Tokuda M. Survivin expression in laryngeal squamous cell carcinomas and its prognostic implications. Anticancer Res 2002; 22: 2377-83.
18. Pizem J, Cör A, Gale N. Survivin expression is a negative prognostic marker in laryngeal squamous cell carcinoma and is associated with p53 accumulation. Histopathology 2004; 45: 180-6.
19. Marioni G, Bertolin A, Giacomelli L, et al. Expression of the apoptosis inhibitor protein survivin in primary, laryngeal carcinoma and cervical lymph node metastases. Anticancer Res 2006; 26: 3813-8.
20. Zhao H, Ren J, Zhuo X, Ye H, Zou J, Liu S. Prognostic significance of survivin and CD44v6 in laryngeal cancer surgical margins. J Cancer Res Clin Oncol 2008; 134: 1051-8.
21. García-Fernández E, De Diego JI, Collantes-Bellido E, et al. Aurora B kinase expression in laryngeal squamous cell carcinoma and its prognostic implications. Histopathology 2011; 58: 368-76.
22. Condon LT, Ashman JN, Ell SR, Stafford ND, Greenman J, Cawkwell L. Overexpression of Bcl-2 in squamous cell carcinoma of the larynx: a marker of radioresistance. Int J Cancer 2002; 100: 472-5.
23. Nix P, Cawkwell L, Patmore H, Greenman J, Stafford N. Bcl-2 expression predicts radiotherapy failure in laryngeal cancer. Br J Cancer 2005; 92: 2185-9.